Prionoids in amyotrophic lateral sclerosis - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Brain Communications Year : 2022

Prionoids in amyotrophic lateral sclerosis


Abstract Amyotrophic lateral sclerosis (ALS) is the third most frequent neurodegenerative disease after Alzheimer’s and Parkinson’s disease. ALS is characterized by the selective and progressive loss of motoneurons in the spinal cord, brainstem and cerebral cortex. Clinical manifestations typically occur in midlife and start with focal muscle weakness, followed by the rapid and progressive wasting of muscles and subsequent paralysis. As with other neurodegenerative diseases, the condition typically begins at an initial point and then spreads along neuroanatomical tracts. This feature of disease progression suggests the spreading of prion-like proteins called prionoids in the affected tissues, which is similar to the spread of prion observed in Creutzfeldt-Jakob disease. Intensive research over the last decade has proposed the ALS-causing gene products Cu/Zn superoxide dismutase 1, TAR DNA-binding protein of 43 kDa, and fused in sarcoma as very plausible prionoids contributing to the spread of the pathology. In this review, we will discuss the molecular and cellular mechanisms leading to the propagation of these prionoids in ALS.
Fichier principal
Vignette du fichier
fcac145.pdf (1.74 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03697999 , version 1 (17-06-2022)



Philippe Gosset, William Camu, Cédric Raoul, Alexandre Mezghrani. Prionoids in amyotrophic lateral sclerosis. Brain Communications, 2022, 4 (3), pp.1 - 16. ⟨10.1093/braincomms/fcac145⟩. ⟨inserm-03697999⟩
2 View
45 Download



Gmail Facebook Twitter LinkedIn More